L299-0530 Screening compound: N-(2H-1,3-benzodioxol-5-yl)-2-methyl-5-{2-methyl-5,8-dioxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,3]diazepin-3-yl}benzene-1-sulfonamide

L299-0530 Screening compound: N-(2H-1,3-benzodioxol-5-yl)-2-methyl-5-{2-methyl-5,8-dioxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,3]diazepin-3-yl}benzene-1-sulfonamide
L299-0530 Screening compound: N-(2H-1,3-benzodioxol-5-yl)-2-methyl-5-{2-methyl-5,8-dioxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,3]diazepin-3-yl}benzene-1-sulfonamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L299-0530
N-(2H-1,3-benzodioxol-5-yl)-2-methyl-5-{2-methyl-5,8-dioxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,3]diazepin-3-yl}benzene-1-sulfonamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L299-0530

Molecular Formula

C22H20N4O6S (C22 H20 N4 O6 S)

Compound Name

N-(2H-1,3-benzodioxol-5-yl)-2-methyl-5-{2-methyl-5,8-dioxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,3]diazepin-3-yl}benzene-1-sulfonamide

IUPAC name

N-(2H-13-benzodioxol-5-yl)-2-methyl-5-{2-methyl-58-dioxo-4H5H6H7H8H-pyrazolo[15-a][13]diazepin-3-yl}benzene-1-sulfonamide

SMILES

Cc(c(-c1cc(S(Nc(cc2)cc3c2OCO3)(=O)=O)c(C)cc1)c1NC(CC2)=O)nn1C2=O

InChI

InChI=1S/C22H20N4O6S/c1-12-3-4-14(21-13(2)24-26-20(28)8-7-19(27)23-22(21)26)9-18(12)33(29,30)25-15-5-6-16-17(10-15)32-11-31-16/h3-6,9-10,25H,7-8,11H2,1-2H3,(H,23,27)

InChI Key

BCCXSRHSFAETSC-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD15123272

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

468.49

Hydrogen Bond Acceptors Count

11.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

4.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

1.764

Distribution Coefficient, logD

0.530

Water Solubility, LogSw

-2.74

Polar Surface Area

110.178

Acid Dissociation Constant (pKa)

6.19

Base Dissociation Constant (pKb)

-2.44

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

22.70

L299-0530 in Drug Discovery

Included in Screening Libraries

Allosteric Kinases Inhibitors Library (23117 compounds)

BRD4 Targeted Library (4534 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

Protein-Protein Interaction Library (218420 compounds)

Anti-HIV1 Library (19540 compounds)

Recognition Elements PPI Library (24135 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Cancer
  • Hemic and lymphatic
  • Cardiovascular
  • Metabolic
  • Antiviral
  • Infections
  • Immune system
Targets:
  • Kinases
  • Others
Mechanism of action:
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics

References: we are preparing a list of scientific research reports with L299-0530 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L299-0530?
Check Price and Availability of L299-0530, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L299-0530 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L299-0530
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L299-0530
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L299-0530 available by request